Zur Therapie der Psoriasis mit Methotrexat

  • K. Enderer
  • U. Froitzheim
  • H. Pullmann
Conference paper
Part of the Verhandlungen der Deutschen Dermatologischen Gesellschaft book series (VDGDERMATOLOGIE, volume 33)

Zusammenfassung

Das zu den Antimetaboliten zählende Methotrexat (MTX) blockiert durch seine Bindung die Dihydrofolsäure-Reduktase und damit die Synthese von Nukleinsäuren. Zellen, die sich rasch teilen, werden durch dieses Zytostatikum in ihrer Synthese-Phase (S-Phase) gestört.

Literatur

  1. 1.
    Luger A (1977) Cytostatika in der Dermatologie. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  2. 2.
    Nyfors A, Brodthagen W (1970) Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 140: 345PubMedCrossRefGoogle Scholar
  3. 3.
    Roenigk H et al (1982) Methotrexate guidelines-revised. Am Acad Dermatol 6: 145CrossRefGoogle Scholar
  4. 4.
    Baker H (1971) Psoriasis, Methotrexate and liver. In: Farber EM, Cox AJ, Jacobs PH (eds) Psoriasis: Proceedings of the First International Symposium. Stanford University PressGoogle Scholar
  5. 5.
    Berlin N et al (1963) Folic acid antagonists: Effect on the cell and the patient, Ann Intern Med 59: 931PubMedGoogle Scholar
  6. 6.
    Paxton JW (1979) High-dose Methotrexate therapy - an area of uncertainty. Aust NZJ Med 9: 722CrossRefGoogle Scholar
  7. 7.
    Chan H et al (1977) Recovery from toxicity associated with high-dose Methotrexate. Cancer Treat Rep 61: 797PubMedGoogle Scholar
  8. 8.
    Pitman S et al (1975) Clinical trial of high-dose Methotrexate with Citrovorum factor - toxicology and therapeutic observations. Cancer Chemother Rep, part 3, 6: 43Google Scholar
  9. 9.
    Condit PT (1960) The acute toxicity of amethopterin in man. Cancer 13: 222PubMedCrossRefGoogle Scholar
  10. 10.
    Land WA (1967) Short term observations in the use of intravenous Methotrexate in the treatment of psoriasis. Aust J Dermatol 9: 183CrossRefGoogle Scholar
  11. 11.
    Feldges DH, Barnes CG (1974) Treatment of psoriatic arthropathy with either Azathioprine or Methotrexate. Rheumatol Rehabil 13: 120PubMedCrossRefGoogle Scholar
  12. 12.
    Bleyer W (1977) Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4: 87PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • K. Enderer
    • 1
  • U. Froitzheim
    • 1
  • H. Pullmann
    • 1
  1. 1.Univ.-HautklinikKöln 41Deutschland

Personalised recommendations